Abstract: Regorafenib (BAY 73-4506) is an oral, multi-target tyrosine kinase inhibitor that has significantly altered the therapeutic landscape for advanced hepatocellular carcinoma (HCC). Approved as a second-line treatment for patients who have progressed on prior sorafenib therapy, regorafenib targets a broad spectrum of angiogenic, stromal, and oncogenic receptors. This review synthesizes the provided literature on regorafenib, detailing its pharmacological activity, molecular mechanisms, and clinical efficacy as demonstrated in the pivotal RESORCE trial. Furthermore, it discusses the current limitations of the drug, including adverse events and resistance, and explores future perspectives, particularly its promising immunomodulatory role when combined with immune checkpoint inhibitors.
1. Introduction
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy and a leading cause of cancer-related mortality worldwide [24]. Because HCC is frequently diagnosed at an advanced stage, curative treatments such as resection or transplantation are often not viable, making systemic therapy the cornerstone of management [46]. For over a decade, the multi-kinase inhibitor sorafenib was the only approved first-line systemic therapy [46]. However, many patients eventually experience disease progression or acquire resistance to sorafenib, highlighting a critical unmet need for effective second-line agents [32]. Regorafenib (BAY 73-4506) emerged as a breakthrough in this setting, becoming the first drug to demonstrate a significant survival benefit for HCC patients in the second-line setting, thereby ushering in the era of sequential targeted therapy [8][32].
2. Pharmacological Activity
The clinical approval of regorafenib for HCC was primarily based on the phase III RESORCE trial, which evaluated its efficacy in patients who tolerated but progressed on prior sorafenib treatment [5][20]. In this trial, regorafenib significantly prolonged the median overall survival (OS) to 10.6 months compared to 7.8 months in the placebo group [5]. Additionally, progression-free survival (PFS) increased from 1.5 months to 3.1 months, and the objective response rate (ORR) was significantly higher (7% vs. 3%) [20]. The introduction of regorafenib established the viability of sequential therapy; studies indicate that sequential treatment with sorafenib followed by regorafenib can yield a median OS of up to 28 months in patients with advanced HCC [5][20]. Beyond its direct anti-tumor effects, long-term administration of regorafenib has been shown to decrease angiogenesis and improve portal hypertension, ameliorating portal hemodynamics in patients with preserved liver function [7].
3. Molecular Mechanism of Action
Regorafenib is an oral small-molecule multikinase inhibitor that targets a wide array of receptor tyrosine kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment [17][36]. Its primary mechanism of action involves the potent blockade of vascular endothelial growth factor receptors (VEGFR 1, 2, and 3), which are critical for tumor neovascularization [7]. In addition to VEGFRs, regorafenib inhibits the angiopoietin receptor Tie-2, platelet-derived growth factor receptor beta (PDGFR-β), fibroblast growth factor receptors (FGFRs), and mutant oncogenic kinases including Kit and Ret [5][20]. By simultaneously blocking these multiple signaling pathways, regorafenib effectively overcomes some of the acquired resistance mechanisms associated with prior sorafenib therapy [7].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the atomic-level structure-activity relationship of regorafenib, its pharmacological profile underscores its design as a highly optimized, multi-targeted agent [17]. Structurally related to earlier kinase inhibitors, regorafenib's molecular configuration allows it to bind and inhibit a broader and more potent spectrum of kinases (such as VEGFRs, Tie-2, PDGFR-β, FGFRs, Kit, and Ret) compared to first-generation drugs [5][20]. This extensive target binding profile is directly responsible for its robust preclinical and clinical antitumor activity, enabling it to succeed where other targeted agents failed in second-line HCC trials [17][32].
5. Current Limitations
Despite its clinical success, the use of regorafenib is accompanied by several limitations. First, its toxicity profile is significant; the incidence of treatment-related grade 3 or 4 adverse events is approximately 50%, with the most common being hand-foot-skin reaction, hypertension, fatigue, and diarrhea [1][5]. Because the pivotal RESORCE trial only included patients who tolerated sorafenib and had well-preserved liver function (Child-Pugh A), the efficacy and safety of regorafenib in sorafenib-intolerant patients or those with more advanced liver dysfunction (Child-Pugh B) remain unestablished [1][18]. Consequently, in real-world clinical practice, only about 30% of patients are eligible for second-line regorafenib treatment [7]. Furthermore, like other targeted therapies, regorafenib provides only a modest prolongation of overall survival before acquired drug resistance eventually limits its efficacy [28].
6. Future Perspectives
The future optimization of regorafenib therapy in HCC relies on improved patient selection and novel combination strategies. The use of liver reserve function biomarkers, such as the albumin-bilirubin (ALBI) grade, has successfully identified optimal candidates for regorafenib, helping to maximize survival outcomes [7]. More importantly, regorafenib is being actively investigated in combination with immunotherapy. Regorafenib exhibits immunomodulatory effects that can enhance the efficacy of anti-PD-1/PD-L1 therapies [17]. A recent multicenter retrospective study demonstrated that combining regorafenib with the anti-PD-1 antibody sintilimab yielded a higher objective response rate (24.1% vs. 9.1%) and a longer median OS (13.4 months) compared to regorafenib monotherapy [54]. Ongoing clinical trials, such as those evaluating regorafenib in combination with pembrolizumab, hold significant promise for overcoming resistance and further improving the prognosis of patients with advanced HCC [61].
